Hyperlipidemia Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The hyperlipidemia market size has grown steadily in recent years. It will grow from $20.24 billion in 2024 to $21.03 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.

The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $24.3 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.

The rising incidence of chronic disorders, particularly heart disease, is expected to drive the growth of the hyperlipidemia market in the future. Heart diseases encompass various conditions that impact the heart and its functioning. Treatment for hyperlipidemia assists individuals with heart disease by reducing the risk of heart attacks, preventing strokes, improving endothelial function, and decreasing the necessity for invasive procedures. For instance, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including about 4 million males and 3.6 million females living with these conditions. These diseases account for around 27% of all deaths in the UK, resulting in over 170,000 deaths each year, or roughly 480 deaths per day, which translates to one death every three minutes. Consequently, the increasing prevalence of chronic disorders such as heart disease is driving the expansion of the hyperlipidemia market.

The increasing prevalence of smoking is expected to drive the growth of the hyperlipidemia market in the future. Smoking involves the consumption of tobacco through combustion, leading to the inhalation of smoke and the absorption of various components into the bloodstream. Smoking is closely linked to risk factors associated with hyperlipidemia, such as obesity and insulin resistance. These risk factors can contribute to dyslipidemia, characterized by abnormal lipid levels, which can eventually lead to the development of hyperlipidemia. For example, in July 2022, Statistics Canada, a Canadian government agency, reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales reaching 1.4 billion in June 2022. Therefore, the growing prevalence of smoking is a driving factor in the hyperlipidemia market.

Key players in the hyperlipidemia market are concentrating on developing innovative products, including advanced therapies for lowering low-density lipoprotein cholesterol, to maintain their market position. For instance, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced the approval of Praluent (alirocumab) Injection by the U.S. Food & Drug Administration (FDA). This represents a significant advancement in the treatment of heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, providing a targeted method to manage dangerously high low-density lipoprotein cholesterol (LDL-C) levels. The recent FDA approval is backed by Phase 3 trial results, which demonstrated a 31% reduction in LDL-C levels with regular dosing. Its well-established safety profile, consistent with that observed in adults, offers reassurance to families and healthcare providers. Additionally, as the first therapy targeting the genetically-validated PCSK9 protein, Praluent marks a milestone in heart disease treatment. Together, these attributes position Praluent as an essential option for managing high cholesterol in children with HeFH.

In March 2022, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology firm, finalized the acquisition of Arena Pharmaceuticals for an undisclosed sum. This strategic move by Pfizer is driven by the company's goal of broadening its product portfolio through the addition of Arena Pharmaceuticals' ongoing clinical-stage projects, which hold promise for the advancement of innovative therapies targeting various immuno-inflammatory diseases. Arena Pharmaceuticals, situated in the United States, is recognized for its specialization in biopharmaceuticals and the development of medications, including those designed to address high cholesterol and hyperlipidemia.

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hyperlipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Hyperlipidemia is a medical condition marked by elevated levels of lipids (fats) in the bloodstream, including cholesterol and triglycerides. This metabolic disorder is common and represents a substantial risk factor for cardiovascular diseases.

Hyperlipidemia can be classified into two main types such as familial and acquired. Familial hyperlipidemia is a genetic disorder characterized by hereditary high lipid levels, notably cholesterol and triglycerides, significantly increasing the risk of cardiovascular diseases. Treatment options encompass medications like statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination therapies, and others. These medications can be administered orally or through injection. They serve various end-users, including hospitals, specialty clinics, home care services, and more.

The hyperlipidemia market research report is one of a series of new reports that provides hyperlipidemia market statistics, including hyperlipidemia industry global market size, regional shares, competitors with a hyperlipidemia market share, detailed hyperlipidemia market segments, market trends and opportunities and any further data you may need to thrive in the hyperlipidemia industry. This hyperlipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.